Vivoryon Therapeutics N.V. Reports Outcome of 2025 Annual General Meeting
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), a clinical stage company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly diabetic kidney disease, held its 2025 Annual General Meeting (AGM) on June 24, 2025.
Shareholders approved all agenda items, including the appointment of Dr. Julia Neugebauer (COO since May 2025) as executive director. The meeting also confirmed the re-appointment of executive directors Dr. Frank Weber and Anne Doering, along with non-executive directors Dr. Erich Platzer, Charlotte Lohmann, Dr. Claudia Riedl, and Dr. Samir Shah.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), un'azienda in fase clinica specializzata nello sviluppo di farmaci a piccole molecole per disturbi infiammatori e fibrotici, in particolare la nefropatia diabetica, ha tenuto la sua Assemblea Generale Annuale (AGM) 2025 il 24 giugno 2025.
Gli azionisti hanno approvato tutti i punti all'ordine del giorno, incluso il nomina della Dott.ssa Julia Neugebauer (COO da maggio 2025) come amministratore esecutivo. L'assemblea ha inoltre confermato la rielezione degli amministratori esecutivi Dott. Frank Weber e Anne Doering, insieme agli amministratori non esecutivi Dott. Erich Platzer, Charlotte Lohmann, Dott.ssa Claudia Riedl e Dott. Samir Shah.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), una empresa en etapa clínica enfocada en desarrollar medicamentos de molécula pequeña para trastornos inflamatorios y fibróticos, especialmente la enfermedad renal diabética, celebró su Asamblea General Anual (AGM) 2025 el 24 de junio de 2025.
Los accionistas aprobaron todos los puntos del orden del día, incluyendo el nombramiento de la Dra. Julia Neugebauer (COO desde mayo de 2025) como directora ejecutiva. La reunión también confirmó la reelección de los directores ejecutivos Dr. Frank Weber y Anne Doering, junto con los directores no ejecutivos Dr. Erich Platzer, Charlotte Lohmann, Dra. Claudia Riedl y Dr. Samir Shah.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY)는 염증 및 섬유화 질환, 특히 당뇨병성 신장 질환을 위한 소분자 약물 개발에 주력하는 임상 단계 회사로서, 2025년 연례 주주총회(AGM)를 2025년 6월 24일에 개최했습니다.
주주들은 모든 안건을 승인했으며, 여기에는 2025년 5월부터 COO로 재직 중인 Julia Neugebauer 박사를 집행 이사로 임명하는 건이 포함되었습니다. 또한 회의에서는 Frank Weber 박사와 Anne Doering 집행 이사, Erich Platzer 박사, Charlotte Lohmann, Claudia Riedl 박사, Samir Shah 박사 등 비집행 이사들의 재선임도 확정했습니다.
Vivoryon Therapeutics N.V. (Euronext Amsterdam : VVY), une société en phase clinique spécialisée dans le développement de médicaments à petites molécules pour les troubles inflammatoires et fibrosants, notamment la maladie rénale diabétique, a tenu son Assemblée Générale Annuelle (AGM) 2025 le 24 juin 2025.
Les actionnaires ont approuvé tous les points à l'ordre du jour, y compris la nomination de la Dre Julia Neugebauer (directrice des opérations depuis mai 2025) en tant que directrice exécutive. L'assemblée a également confirmé la réélection des directeurs exécutifs Dr Frank Weber et Anne Doering, ainsi que des administrateurs non exécutifs Dr Erich Platzer, Charlotte Lohmann, Dr Claudia Riedl et Dr Samir Shah.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), ein klinisch tätiges Unternehmen, das sich auf die Entwicklung von niedermolekularen Medikamenten für entzündliche und fibrotische Erkrankungen, insbesondere diabetische Nierenerkrankungen, spezialisiert hat, hielt am 24. Juni 2025 seine Jahreshauptversammlung (AGM) 2025 ab.
Die Aktionäre genehmigten alle Tagesordnungspunkte, einschließlich der Ernennung von Dr. Julia Neugebauer (seit Mai 2025 COO) als geschäftsführendes Vorstandsmitglied. Die Versammlung bestätigte zudem die Wiederernennung der geschäftsführenden Vorstände Dr. Frank Weber und Anne Doering sowie der nicht geschäftsführenden Vorstände Dr. Erich Platzer, Charlotte Lohmann, Dr. Claudia Riedl und Dr. Samir Shah.
- None.
- None.
Vivoryon Therapeutics N.V. Reports Outcome
of 2025 Annual General Meeting
Halle (Saale) / Munich, Germany, June 24, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on diabetic kidney disease, held its Annual General Meeting (AGM) today at 1:00 p.m. (CEST). The shareholders approved all items on the agenda of the meeting, including the appointment of Dr. Julia Neugebauer, COO of Vivoryon since May 2025, to the Company’s Board as executive director. The re-appointment of Dr. Frank Weber and Anne Doering as executive directors, as well as the re-appointment of Dr. Erich Platzer, Charlotte Lohmann, Dr. Claudia Riedl and Dr. Samir Shah as non-executive directors to the Company’s Board were also confirmed by Vivoryon’s shareholders.
All documents relating to the AGM are available on the Company’s website: https://www.vivoryon.com/2025-annual-general-meeting/
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of proteins which are altered in disease settings. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com
Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.
For more information, please contact:
Investor Contacts
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com
LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com
Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email: vivoryon@trophic.eu
Attachment
FAQ
When did Vivoryon Therapeutics (VVY) hold its 2025 Annual General Meeting?
Who was newly appointed to Vivoryon's Board at the 2025 AGM?
Which directors were re-appointed at Vivoryon's 2025 AGM?
Where can investors find documents related to Vivoryon's 2025 AGM?
